2/17
08:45 am
omer
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
Low
Report
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
1/27
10:59 am
omer
Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Medium
Report
Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
1/27
09:00 am
omer
Omeros Announces First Commercial Sales of YARTEMLEA®
Medium
Report
Omeros Announces First Commercial Sales of YARTEMLEA®
1/16
06:55 am
omer
Thrombotic Microangiopathy Global Clinical Trials Market Review Report 2025 [Yahoo! Finance]
Low
Report
Thrombotic Microangiopathy Global Clinical Trials Market Review Report 2025 [Yahoo! Finance]
1/8
08:23 am
omer
Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Medium
Report
Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
1/8
08:23 am
omer
Omeros (NASDAQ:OMER) had its price target raised by analysts at HC Wainwright from $20.00 to $40.00. They now have a "buy" rating on the stock.
Medium
Report
Omeros (NASDAQ:OMER) had its price target raised by analysts at HC Wainwright from $20.00 to $40.00. They now have a "buy" rating on the stock.
12/26
06:43 pm
omer
Omeros Announces New Date for YARTEMLEA® Approval Conference Call [Yahoo! Finance]
Medium
Report
Omeros Announces New Date for YARTEMLEA® Approval Conference Call [Yahoo! Finance]
12/26
06:36 pm
omer
Omeros Announces New Date for YARTEMLEA® Approval Conference Call
Medium
Report
Omeros Announces New Date for YARTEMLEA® Approval Conference Call
12/10
02:27 pm
omer
Omeros Corporation (OMER): Novo Nordisk Deal Creating Buzz [Yahoo! Finance]
Low
Report
Omeros Corporation (OMER): Novo Nordisk Deal Creating Buzz [Yahoo! Finance]
12/1
01:23 pm
omer
Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Low
Report
Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
12/1
08:41 am
omer
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) [Yahoo! Finance]
Medium
Report
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) [Yahoo! Finance]
12/1
08:30 am
omer
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)
Medium
Report
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)